LEADER 03883nam  22007572  450 
001 9910789706403321
005 20151005020622.0
010   $a1-139-20910-8
010   $a1-107-22347-4
010   $a1-280-48477-2
010   $a9786613579751
010   $a1-139-22181-7
010   $a1-139-21699-6
010   $a1-139-22352-6
010   $a1-139-21392-X
010   $a1-139-22009-8
010   $a1-139-02692-5
035   $a(CKB)2670000000131847
035   $a(EBL)833378
035   $a(OCoLC)775869725
035   $a(SSID)ssj0000572812
035   $a(PQKBManifestationID)11364731
035   $a(PQKBTitleCode)TC0000572812
035   $a(PQKBWorkID)10541034
035   $a(PQKB)10250166
035   $a(UkCbUP)CR9781139026925
035   $a(Au-PeEL)EBL833378
035   $a(CaPaEBR)ebr10533290
035   $a(CaONFJC)MIL357975
035   $a(MiAaPQ)EBC833378
035   $a(PPN)261332244
035   $a(EXLCZ)992670000000131847
100   $a20110218d2012||||  uy|            0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aXenotransplantation and risk $eregulating a developing biotechnology /$fSara Fovargue$b[electronic resource]
210  1$aCambridge :$cCambridge University Press,$d2012.
215   $a1 online resource (xiii, 291 pages) $cdigital, PDF file(s)
225 1 $aCambridge law, medicine, and ethics ;$v14
300   $aTitle from publisher's bibliographic system (viewed on 05 Oct 2015).
311   $a0-521-19576-4 
320   $aIncludes bibliographical references and index.
327   $aIntroducing the issues -- Dealing with risk -- Regulating experimental procedures and medical research -- Regulatory responses to developing biotechnologies -- Challenges to legal and ethical norms : first party consent and third parties at risk -- Surveillance and monitoring : balancing public health and individual freedom -- Summary and concluding thoughts : looking to the future.
330   $aSome developing biotechnologies challenge accepted legal and ethical norms because of the risks they pose. Xenotransplantation (cross-species transplantation) may prolong life but may also harm the xeno-recipient and the public due to its potential to transmit infectious diseases. These trans-boundary diseases emphasise the global nature of advances in health care and highlight the difficulties of identifying, monitoring and regulating such risks and thereby protecting individual and public health. Xenotransplantation raises questions about how uncertainty and risk are understood and accepted, and exposes tensions between private benefit and public health. Where public health is at risk, a precautionary approach informed by the harm principle supports prioritising the latter, but the issues raised by genetically engineered solid organ xenotransplants have not, as yet, been sufficiently discussed. This must occur prior to their clinical introduction because of the necessary changes to accepted norms which are needed to appropriately safeguard individual and public health.
410  0$aCambridge law, medicine, and ethics ;$v14.
517 3 $aXenotransplantation & Risk
606   $aXenografts
606   $aTransplantation immunology
606   $aXenografts$xMoral and ethical aspects
606   $aTransplantation of organs, tissues, etc
615  0$aXenografts.
615  0$aTransplantation immunology.
615  0$aXenografts$xMoral and ethical aspects.
615  0$aTransplantation of organs, tissues, etc.
676   $a344.04/194
686   $aLAW093000$2bisacsh
700   $aFovargue$b Sara$f1971-$01052865
801  0$bUkCbUP
801  1$bUkCbUP
906   $aBOOK
912   $a9910789706403321
996   $aXenotransplantation and risk$93682940
997   $aUNINA